NCT00391053View on ClinicalTrials.gov

Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly

PHASE3CompletedINTERVENTIONAL
Enrollment

3,851

Participants

Timeline

Start Date

October 31, 2006

Primary Completion Date

July 31, 2007

Study Completion Date

February 29, 2008

Conditions
Orthomyxoviridae InfectionInfluenzaMyxovirus Infection
Interventions
BIOLOGICAL

High-Dose Inactivated, Split-Virion Influenza Vaccine

0.5 mL, IM

BIOLOGICAL

High-Dose Inactivated, Split-Virion Influenza Vaccine

0.5 mL, IM

BIOLOGICAL

High-Dose Inactivated, Split-Virion Influenza Vaccine

0.5 mL, IM

BIOLOGICAL

Inactivated, Split-Virion Influenza Vaccine

0.5 mL, IM

Trial Locations (28)

Unknown

Mesa

Phoenix

Tempe

Tucson

San Diego

Stratford

Clearwater

Coral Gables

Orlando

Pembroke Pines

Wichita

Rockville

Rochester

Kansas City

St Louis

Endwell

Rochester

Cary

Raleigh

Downington

Erie

Warwick

Dallas

Plano

West Jordan

Norfolk

Richmond

Marshfield

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00391053 - Immunogenicity of High-dose Inactivated, Split-virion Influenza Vaccine Versus Standard Fluzone Vaccine in the Elderly | Biotech Hunter | Biotech Hunter